Angiogenesis is confined to the transient period of VEGF expression that follows adenoviral gene delivery to ischemic muscle - PubMed (original) (raw)
Angiogenesis is confined to the transient period of VEGF expression that follows adenoviral gene delivery to ischemic muscle
M J Gounis et al. Gene Ther. 2005 May.
Abstract
Therapeutic angiogenesis involves the introduction of exogenous growth factor proteins and genes into ischemic tissues to augment endogenous factors and promote new vessel growth. Positive results from studies in animal models of peripheral arterial disease (PAD) and coronary artery disease over the past decade have supported the implementation of clinical trials testing vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) proteins and genes. Although several clinical trials reported positive results, others have been disappointing and results of a recent Phase II trial of VEGF delivered by adenovirus (the RAVE trial) were negative. It has been suggested that the duration of gene expression following delivery by adenovirus may be insufficient to produce stable vessels. Here we present direct evidence in support of this using the rabbit ischemic hindlimb model injected with adenovirus encoding VEGF165. Immunohistology indicated an activation of endothelial cell cycling and proliferation 2-3 days after VEGF delivery that coincided closely with transient VEGF expression. Ki-67-positive endothelial nuclei were evident at high levels in capillaries and large vessels in muscles from treated animals. Angiography indicated increased density of both large and small vessels in Ad-VEGF-treated muscle at 1 week, but no significant differences thereafter. The early burst of endothelial proliferation was accompanied by increased nuclear fragmentation and condensation in VEGF-treated muscles, suggesting coincident apoptosis. No further endothelial cell proliferation took place after 1 week although there was still evidence of apoptosis. The results suggest that angiogenesis is confined to the short period of VEGF expression produced by adenovirus and early gains in collateralization rapidly regress to control levels when VEGF production ceases.
Similar articles
- Increased revascularization efficacy after administration of an adenovirus encoding VEGF(121).
Perrin LA, June JE, Rosebury W, Robertson A, Kovesdi I, Bruder JT, Kessler PD, Keiser JA, Gordon D. Perrin LA, et al. Gene Ther. 2004 Mar;11(6):512-21. doi: 10.1038/sj.gt.3302173. Gene Ther. 2004. PMID: 14999223 - Evaluation of angiogenesis and side effects in ischemic rabbit hindlimbs after intramuscular injection of adenoviral vectors encoding VEGF and LacZ.
Vajanto I, Rissanen TT, Rutanen J, Hiltunen MO, Tuomisto TT, Arve K, Närvänen O, Manninen H, Räsänen H, Hippeläinen M, Alhava E, Ylä-Herttuala S. Vajanto I, et al. J Gene Med. 2002 Jul-Aug;4(4):371-80. doi: 10.1002/jgm.287. J Gene Med. 2002. PMID: 12124979 - VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses.
Rissanen TT, Markkanen JE, Gruchala M, Heikura T, Puranen A, Kettunen MI, Kholová I, Kauppinen RA, Achen MG, Stacker SA, Alitalo K, Ylä-Herttuala S. Rissanen TT, et al. Circ Res. 2003 May 30;92(10):1098-106. doi: 10.1161/01.RES.0000073584.46059.E3. Epub 2003 Apr 24. Circ Res. 2003. PMID: 12714562 - [Therapeutic angiogenesis through intramuscular injection of the gene for vascular endothelial growth factor (VEGF)].
Banga JD. Banga JD. Ned Tijdschr Geneeskd. 2000 Jan 15;144(3):113-6. Ned Tijdschr Geneeskd. 2000. PMID: 10674116 Review. Dutch. - Gene transfer for therapeutic vascular growth in myocardial and peripheral ischemia.
Rissanen TT, Rutanen J, Ylä-Herttuala S. Rissanen TT, et al. Adv Genet. 2004;52:117-64. doi: 10.1016/S0065-2660(04)52004-7. Adv Genet. 2004. PMID: 15522734 Review.
Cited by
- Stromal-Cell-Derived Factor-1 (SDF-1)/CXCL12 as Potential Target of Therapeutic Angiogenesis in Critical Leg Ischaemia.
Ho TK, Shiwen X, Abraham D, Tsui J, Baker D. Ho TK, et al. Cardiol Res Pract. 2012;2012:143209. doi: 10.1155/2012/143209. Epub 2012 Feb 22. Cardiol Res Pract. 2012. PMID: 22462026 Free PMC article. - Human studies of angiogenic gene therapy.
Gupta R, Tongers J, Losordo DW. Gupta R, et al. Circ Res. 2009 Oct 9;105(8):724-36. doi: 10.1161/CIRCRESAHA.109.200386. Circ Res. 2009. PMID: 19815827 Free PMC article. Review. - Transplantation of modified human adipose derived stromal cells expressing VEGF165 results in more efficient angiogenic response in ischemic skeletal muscle.
Shevchenko EK, Makarevich PI, Tsokolaeva ZI, Boldyreva MA, Sysoeva VY, Tkachuk VA, Parfyonova YV. Shevchenko EK, et al. J Transl Med. 2013 Jun 6;11:138. doi: 10.1186/1479-5876-11-138. J Transl Med. 2013. PMID: 23742074 Free PMC article. - Vascular regeneration by local growth factor release is self-limited by microvascular clearance.
Le KN, Hwang CW, Tzafriri AR, Lovich MA, Hayward A, Edelman ER. Le KN, et al. Circulation. 2009 Jun 9;119(22):2928-35. doi: 10.1161/CIRCULATIONAHA.108.823609. Epub 2009 May 26. Circulation. 2009. PMID: 19470891 Free PMC article. - Enhanced notch signaling modulates unproductive revascularization in response to nitric oxide-angiopoietin signaling in a mouse model of peripheral ischemia.
Machado MJC, Boardman R, Riu F, Emanueli C, Benest AV, Bates DO. Machado MJC, et al. Microcirculation. 2019 Aug;26(6):e12549. doi: 10.1111/micc.12549. Epub 2019 Jun 19. Microcirculation. 2019. PMID: 30974486 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous